Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Nov 6, 2024
Distillery Therapeutics
Inhibiting NOGO for hypercholesterolemia
Read More
BioCentury
|
May 3, 2023
Product Development
Rationale for ROCK2 in rare neurological disorders
Why Ovid and Sam Waksal newco Graviton are first tackling a rare seizure disorder with a target that may have a role in diverse indications
Read More
BioCentury
|
Jun 26, 2019
Distillery Therapeutics
RTN4 and S1PR2 identified as targets for stroke
Read More
BioCentury
|
Aug 4, 2017
Company News
ReNetX Bio launches with chronic SCI candidate
Read More
BioCentury
|
Jan 11, 2017
Distillery Therapeutics
Neurology
Read More
BioCentury
|
Jul 17, 2014
Distillery Therapeutics
Indication: Neurology
Read More
BioCentury
|
Jul 29, 2013
Company News
GlaxoSmithKline neurology news
Read More
BioCentury
|
Dec 10, 2012
Company News
AlphaCore Pharma LLC, Axerion Therapeutics, Optimum Therapeutics LLC, NIH cancer, cardiovascular, neurology news
Read More
BioCentury
|
Dec 5, 2012
Politics & Policy
NIH selects three more projects for BrIDGs program
Read More
BioCentury
|
Jul 14, 2011
Targets & Mechanisms
NOGO could go far
Read More
Items per page:
10
1 - 10 of 37
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help